Cargando…

Use of Glycoproteins—Prostate-Specific Membrane Antigen and Galectin-3 as Primary Tumor Markers and Therapeutic Targets in the Management of Metastatic Prostate Cancer

SIMPLE SUMMARY: Prostate specific membrane antigen and galectins are proteins expressed on cell surface and their expression is associated with cancer growth and spread. The goal of this research was to look at the pattern of these two glycoproteins in the human prostate cancer microenvironment. Pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Satish, Cwiklinski, Katherine, Sykes, Donald E., Mahajan, Supriya D., Chevli, Kent, Schwartz, Stanley A., Aalinkeel, Ravikumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179331/ https://www.ncbi.nlm.nih.gov/pubmed/35681683 http://dx.doi.org/10.3390/cancers14112704

Ejemplares similares

Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells
por: Sharma, Satish, et al.
Publicado: (2023)

Neuroprotective role of galectin-1 in central nervous system pathophysiology
por: Aalinkeel, Ravikumar, et al.
Publicado: (2016)

Genomic Analysis Highlights the Role of the JAK-STAT Signaling in the Anti-proliferative Effects of Dietary Flavonoid—‘Ashwagandha’ in Prostate Cancer Cells
por: Aalinkeel, Ravikumar, et al.
Publicado: (2010)

IL-17 Is a Key Regulator of Mucin-Galectin-3 Interactions in Asthma
por: Mammen, Manoj J., et al.
Publicado: (2021)

Microbial Biofilm: A Review on Formation, Infection, Antibiotic Resistance, Control Measures, and Innovative Treatment
por: Sharma, Satish, et al.
Publicado: (2023)

PO262 / #255 NEUROMODULATORY EFFECTS OF SARS-COV2 ON BLOOD BRAIN BARRIER INTEGRITY AND FUNCTION: E-POSTER VIEWING
por: Clough, Erin, et al.
Publicado: (2022)

Proteomic Approach to Evaluate Mechanisms That Contribute to Food Allergenicity: Comparative 2D-DIGE Analysis of Radioallergosorbent Test Positive and Negative Patients
por: Nair, Bindukumar, et al.
Publicado: (2011)

Effector cell mediated cytotoxicity measured by intracellular Granzyme B release in HIV infected subjects
por: Mahajan, Supriya D., et al.
Publicado: (2003)

Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA
por: Mahajan, Supriya D., et al.
Publicado: (2011)

Effect of pretreatment prostate volume on urinary quality of life following intensity-modulated radiation therapy for localized prostate cancer
por: Chevli, Connor, et al.
Publicado: (2013)

Anti-HIV-1 nanotherapeutics: promises and challenges for the future
por: Mahajan, Supriya D, et al.
Publicado: (2012)

Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer
por: Bruggemann, Liana, et al.
Publicado: (2023)

Mitochondrial Dynamics in SARS-COV2 Spike Protein Treated Human Microglia: Implications for Neuro-COVID
por: Clough, Erin, et al.
Publicado: (2021)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers
por: Laderach, Diego J., et al.
Publicado: (2013)

The significance of galectin-3 as a new basal cell marker in prostate cancer
por: Wang, Y, et al.
Publicado: (2013)

Low incidence of prostate cancer identified in the transition and anterior zones with transperineal biopsy
por: Danforth, Teresa L, et al.
Publicado: (2012)

Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer
por: Gentilini, Lucas Daniel, et al.
Publicado: (2017)

Sensorimotor polyneuropathy and foot-drop as result of a prostate cancer paraneoplastic syndrome
por: Bodkin, John J, et al.
Publicado: (2013)

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
por: Raju, Govinda Nanjaiah Laxmana, et al.
Publicado: (2022)

Synthesis of the Thomsen-Friedenreich-antigen (TF-antigen) and binding of Galectin-3 to TF-antigen presenting neo-glycoproteins
por: Hoffmann, Marius, et al.
Publicado: (2020)

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
por: Fosså, S. D., et al.
Publicado: (1992)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Comparative analysis of MTP -493G/T and ABCG2 34G/A polymorphisms and theirs expression in HIV-associated lipodystrophy patients
por: Singh, HariOm, et al.
Publicado: (2023)

Extremely Elevated Prostate-Specific Antigen in Acute Prostatitis: A Case Report
por: Nepal, Anamika, et al.
Publicado: (2023)

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
por: Yaxley, William John, et al.
Publicado: (2021)

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012)

Expression of NKX3.1, Prostatic Specific Antigen and Prostatic Specific Alkaline Phosphatase in Cytology Specimens of Metastatic Prostatic Carcinoma
por: Wang, Minhua, et al.
Publicado: (2021)

Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor
por: Souza, Deborah Simão, et al.
Publicado: (2023)

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

Survival in Patients With Metastatic Prostate Cancer Undergoing Radiotherapy: The Importance of Prostate-Specific Antigen-Based Stratification
por: Tian, Zijian, et al.
Publicado: (2021)

Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
por: Teoh, Jeremy YC, et al.
Publicado: (2017)

Gene Silencing of Human Neuronal Cells for Drug Addiction Therapy using Anisotropic Nanocrystals
por: Law, Wing-Cheung, et al.
Publicado: (2012)

Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
por: Hillerdal, Victoria, et al.
Publicado: (2015)

A mechanistic insight into the anti-metastatic role of the prostate specific antigen
por: Pellegrino, Francesco, et al.
Publicado: (2021)

Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma
por: Yin, Ming, et al.
Publicado: (2007)

Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
por: Ghosn, Marwan, et al.
Publicado: (2015)

The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
por: Kiper, Ahmet, et al.
Publicado: (2005)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s2cp9mqpc59sta845vj972kn29